Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;2015:923194.
doi: 10.1155/2015/923194. Epub 2015 Feb 19.

Ascertainment and Verification of End-Stage Renal Disease and End-Stage Liver Disease in the North American AIDS Cohort Collaboration on Research and Design

Affiliations
Free PMC article

Ascertainment and Verification of End-Stage Renal Disease and End-Stage Liver Disease in the North American AIDS Cohort Collaboration on Research and Design

Mari M Kitahata et al. AIDS Res Treat. .
Free PMC article

Abstract

The burden of HIV disease has shifted from traditional AIDS-defining illnesses to serious non-AIDS-defining comorbid conditions. Research aimed at improving HIV-related comorbid disease outcomes requires well-defined, verified clinical endpoints. We developed methods to ascertain and verify end-stage renal disease (ESRD) and end-stage liver disease (ESLD) and validated screening algorithms within the largest HIV cohort collaboration in North America (NA-ACCORD). Individuals who screened positive among all participants in twelve cohorts enrolled between January 1996 and December 2009 underwent medical record review to verify incident ESRD or ESLD using standardized protocols. We randomly sampled 6% of contributing cohorts to determine the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of ESLD and ESRD screening algorithms in a validation subcohort. Among 43,433 patients screened for ESRD, 822 screened positive of which 620 met clinical criteria for ESRD. The algorithm had 100% sensitivity, 99% specificity, 82% PPV, and 100% NPV for ESRD. Among 41,463 patients screened for ESLD, 2,024 screened positive of which 645 met diagnostic criteria for ESLD. The algorithm had 100% sensitivity, 95% specificity, 27% PPV, and 100% NPV for ESLD. Our methods proved robust for ascertainment of ESRD and ESLD in persons infected with HIV.

Similar articles

See all similar articles

Cited by 8 articles

See all "Cited by" articles

References

    1. Palella F. J., Jr., Baker R. K., Moorman A. C., et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. Journal of Acquired Immune Deficiency Syndromes. 2006;43(1):27–34. doi: 10.1097/01.qai.0000233310.90484.16. - DOI - PubMed
    1. The Antiretroviral Therapy Cohort Collaboration (ART-CC) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. The Lancet. 2008;372(9635):293–299. doi: 10.1016/s0140-6736(08)61113-7. - DOI - PMC - PubMed
    1. Lohse N., Hansen A.-B. E., Pedersen G., et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Annals of Internal Medicine. 2007;146(2):87–95. doi: 10.7326/0003-4819-146-2-200701160-00003. - DOI - PubMed
    1. Losina E., Schackman B. R., Sadownik S. N., et al. Racial and sex disparities in life expectancy losses among hiv-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clinical Infectious Diseases. 2009;49(10):1570–1578. doi: 10.1086/644772. - DOI - PMC - PubMed
    1. Currier J. S., Lundgren J. D., Carr A., et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118(6):e29–e35. doi: 10.1161/CIRCULATIONAHA.107.189624. - DOI - PMC - PubMed

Grant support

Feedback